Targeting Angiogenesis With Peptide Vaccines

Rahat, Michal A.

doi:10.3389/fimmu.2019.01924

Cited by 15 publications

(9 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our research demonstrated that the expression and secretion of VEGFA was regulated by LBH in glioma cell lines and GSCs, the exact transcriptional mechanism of LBH on VEGFA requires further study. Moreover, VEGF is a vital treatment target for anti-tumor therapy, and there are several VEGF-targeting drugs, such as bevacizumab [46,47]. It is possible that patients with increased LBH expression may be sensitive to anti-VEGF therapy.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia

et al. 2019

View full text Add to dashboard Cite

Background: Glioma is the most common primary malignant tumor in the central nervous system with frequent hypoxia and angiogenesis. Limb-Bud and Heart (LBH) is a highly conserved transcription cofactor that participates in embryonic development and tumorigenesis. Methods: The conditioned media from LBH regulated human glioma cell lines and patient-derived glioma stem cells (GSCs) were used to treat the human brain microvessel endothelial cells (hBMECs). The function of LBH on angiogenesis were examined through methods of MTS assay, Edu assay, TUNEL assay, western blotting analysis, qPCR analysis, luciferase reporter assay and xenograft experiment. Findings: Our study found for the first time that LBH was overexpressed in gliomas and was associated with a poor prognosis. LBH overexpression participated in the angiogenesis of gliomas via the vascular endothelial growth factor A (VEGFA)-mediated extracellular signal-regulated kinase (ERK) signalling pathway in human brain microvessel endothelial cells (hBMECs). Rapid proliferation of gliomas can lead to tissue hypoxia and hypoxia inducible factor-1 (HIF-1) activation, while HIF-1 can directly transcriptionally regulate the expression of LBH and result in a self-reinforcing cycle. Interpretation: LBH may be a possible treatment target to break the vicious cycle in glioma treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Hence, to overcome this, Mabs can be attached to a nanocarrier surface via a pre-adsorption process and prevent biomolecular corona formation [ 190 , 191 ]. The nature of HGG, mainly GBM cells, which are incredibly heterogenic, makes the usage of monovalent vaccines inadequate to control tumor progression [ 192 , 193 , 194 ]. For example, some peptide vaccines are vastly restricted towards the EGFR V III variant, which is only present in 23–33% of GBM patients [ 195 , 196 ].…”

Section: Drug Development For Hgg: Advancements and Challengesmentioning

confidence: 99%

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas

et al. 2021

View full text Add to dashboard Cite

Despite their low incidence rate globally, high-grade gliomas (HGG) remain a fatal primary brain tumor. The recommended therapy often is incapable of resecting the tumor entirely and exclusively targeting the tumor leads to tumor recurrence and dismal prognosis. Additionally, many HGG patients are not well suited for standard therapy and instead, subjected to a palliative approach. HGG tumors are highly infiltrative and the complex tumor microenvironment as well as high tumor heterogeneity often poses the main challenges towards the standard treatment. Therefore, a one-fit-approach may not be suitable for HGG management. Thus, a multimodal approach of standard therapy with immunotherapy, nanomedicine, repurposing of older drugs, use of phytochemicals, and precision medicine may be more advantageous than a single treatment model. This multimodal approach considers the environmental and genetic factors which could affect the patient’s response to therapy, thus improving their outcome. This review discusses the current views and advances in potential HGG therapeutic approaches and, aims to bridge the existing knowledge gap that will assist in overcoming challenges in HGG.

show abstract

“…Both autoreactive immune cells and their secreted cytokines can result in harmful autoreactive immune attacks towards host cells and tissues, and thus, they are the two main targets for immunotherapy in rheumatic diseases. Distinct forms of peptide-based vaccinations have been studied for therapeutic or preventive strategies for diseases such as cancer, rheumatic diseases, and allergic disorders [34][35][36][37][38]. According to the therapeutic targets, peptide-based vaccinations used for rheumatic diseases can be classified into two main subtypes including peptide-based active vaccination against pathogenic cytokines and peptide-based tolerogenic vaccination.…”

Section: Types Of Peptide-based Vaccination Therapymentioning

confidence: 99%

“…Many peptide autoepitopes have been proven to be involved in the pathogenesis of SLE [167][168][169]. Some histone peptides such as histone H4 autoepitope peptide 16-39 (H4 ) and autoepitope peptide 71-94 (H4 ) could induce an inflammatory response, whereas others such as H2A [34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] could lead to an immunosuppressive response [167,168]. Therefore, different peptides can lead to distinct immune response during the development of SLE.…”

Section: Journal Of Immunology Researchmentioning

confidence: 99%

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Wang

Chen

Zheng

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Rheumatic diseases are extremely heterogeneous diseases with substantial risks of morbidity and mortality, and there is a pressing need in developing more safe and cost-effective treatment strategies. Peptide-based vaccination is a highly desirable strategy in treating noninfection diseases, such as cancer and autoimmune diseases, and has gained increasing attentions. This review is aimed at providing a brief overview of the recent advances in peptide-based vaccination therapy for rheumatic diseases. Tremendous efforts have been made to develop effective peptide-based vaccinations against rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while studies in other rheumatic diseases are still limited. Peptide-based active vaccination against pathogenic cytokines such as TNF-α and interferon-α (IFN-α) is shown to be promising in treating RA or SLE. Moreover, peptide-based tolerogenic vaccinations also have encouraging results in treating RA or SLE. However, most studies available now have been mainly based on animal models, while evidence from clinical studies is still lacking. The translation of these advances from experimental studies into clinical therapy remains impeded by some obstacles such as species difference in immunity, disease heterogeneity, and lack of safe delivery carriers or adjuvants. Nevertheless, advances in high-throughput technology, bioinformatics, and nanotechnology may help overcome these impediments and facilitate the successful development of peptide-based vaccination therapy for rheumatic diseases.

show abstract

Targeting Angiogenesis With Peptide Vaccines

Cited by 15 publications

References 81 publications

Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia

Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Contact Info

Product

Resources

About